SOHL yields 20000000.00% · ABBV yields 3.06%● Live data
📍 SOHL pulled ahead of the other in Year 1
Combined, SOHL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SOHL + ABBV for your $10,000?
Southern Trust Securities Holding Corp., through its subsidiaries, provides broker-dealer, investment banking, asset management, and investment advisory services in the United States. The company offers its clients access to domestic and international securities and options exchanges; trading in fixed income products, corporate, government, agencies, municipals, and emerging market debt; fixed and variable annuities and life insurance; various domestic and international mutual funds; and management of retirement plans, such as 401ks, 403bs, retirement accounts, and other plans. It also provides portfolio management for individuals, pension funds, retirement plans, foundations, trusts, and corporations; corporate services facilitating restricted stock dispositions and stock option exercises; and offshore services, which enable client access to foreign trusts and corporations. In addition, the company offers traditional and innovative securities transaction structures; merger and acquisition advisory services; private placements convertible into publicly-traded shares; and private placements bridging to public offerings through reverse mergers into publicly-traded shell corporations. Further, it trades in precious metals, such as gold, silver, platinum, and palladium. The company was founded in 1998 and is headquartered in Coral Gables, Florida.
Full SOHL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.